3/25(Sat) Plenary Speaker
陳垣崇 Dr. Yuan-Tsong Chen
Institute of Biomedical Sciences Academia Sinica, Distinguished Research Fellow
Professor Yuan-Tsong (Y-T) Chen received his MD degree from National Taiwan University (Taipei) and PhD from Columbia University (USA). He is Director Emeritus and Distinguished Research Fellow of the Institute of Biomedical Sciences, Academia Sinica, Taiwan, and Tenure Professor of Pediatrics at Duke University Medical Center (USA). Professor Chen is a physician/scientist, recognized for his work on human genetic disorders. His translational research leads to the development of now standard therapies for two devastating inherited metabolic diseases: severe hypoglycemia in glycogen storage diseases and Pompe disease. Professor Chen has also identified the genetic basis of and developed DNA-based diagnosis for several major heritable diseases, and more recently, his research focuses on the pharmacogenetics of adverse drug reaction. His team has discovered genetic basis of warfarin sensitivity and drug-induced Stevens Johnson syndrome. Professor Chen is an elected member of Academia Sinica and of The World Academy of Science.
3/26(Sun) Plenary Speaker
張子文 Dr. Tse-Wen Chang
Immunwork, Inc. Founder and CEO
Dr. Tse-Wen Chang dedicates his research career to the invention and development of new drugs for treating severe diseases. Dr. Chang cofounded Tanox in Houston, Texas in 1986 and invented in 1987 the anti-IgE therapy, leading to the development of omalizumab (Xolair), now approved for severe allergic asthma in more than 100 countries and for severe chronic spontaneous urticaria in many countries. While in Academia Sinica, his group developed two new antibody drugs, an anti-CemX and a new form of anti-IgE, which target the IgE pathway by different mechanisms. These two candidates (FB825 and UB221) have been respectively licensed to two companies in Taiwan for clinical development. Dr. Chang has retired from Academia Sinica and is now leading a team in Immunwork, Inc., which he founded in 2014, to develop T-E pharmaceuticals, which have both targeting and effector moieties, for applications in oncology, autoimmune, infectious, CNS, and other diseases.